Refine by
Microbiome Analysis Articles & Analysis: Older
19 news found
Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the standard for next-generation routine microbiome analysis with its Precision Microbiome Profiling (PMP™) platform. PMP™ enables rapid, accurate, ...
ByBio-Me
(Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (“Ares”), which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), is commercially launching a series of new ...
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. ...
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. ...
ByBio-Me
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand the significance ...
Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. ...
ByBio-Me
Bio-Me today announced a major board restructuring with Carl Christian Glilhuus-Moe stepping up to the Executive Chair position. He is joined by new board members Hilde Furberg, Anne-Marie Duus Kristensen, and Arne Materna who collectively bring a wealth of diagnostic, microbiology, and commercialization experience as the Company enters a new phase of development following a recent successful ...
ByBio-Me
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, clinically designed in the same ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that MB097 is now in pre-clinical development for treatment of patients not responding to anti-PD1 therapy. Clinical trials are due to begin in 2022. MB097 is clinically designed and experimentally validated. Studies have shown that the gut microbiome plays a critical and causative role in determining ...
“There is considerable interest in microbiome modulation to enhance immune checkpoint inhibitor efficacy that is more consistent and scalable than fecal transplants. ...
The company will provide Intus Biosciences instruments, microbiome kits and analysis software to companies and research organizations all across Germany, Austria and Switzerland. ...
Intus Biosciences, a microbiome research company that develops solutions for characterizing microbiome populations down to the strain level, recently unveiled a powerful new high molecular weight (HMW) DNA prep solution supporting microbial metagenomics applications. ...
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
Intus Biosciences, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, was recently awarded a new patent by the United States Patent and Trademark Office. ...
Microbiome Dx company Bio-Me and Siolta Therapeutics today announced that they have entered into a collaboration and marketing agreement. Under the agreement, Siolta will provide both samples and insights into key criteria for Bio-Me to develop a rapid, detailed and comprehensive diagnostic test for infants at risk of developing allergy and asthma. The test will be offered to parents of ...
Microbiome Dx company Bio-Me and Siolta Therapeutics today announced that they have entered into a collaboration and marketing agreement. Under the agreement, Siolta will provide both samples and insights into key criteria for Bio-Me to develop a rapid, detailed and comprehensive diagnostic test for infants at risk of developing allergy and asthma. The test will be offered to parents of ...
ByBio-Me
The investigational microbiome-based formulations, RBX2660 and RBX7455, are in development for the reduction of rCDI. ...
Bio-Me, a pioneer in rapid gut microbiome analysis is announcing the opening of its gut microbiome analysis service laboratory. ...
ByBio-Me
” says Marcus Meadows-Smith, CEO “This new funding allows us to increase our annual spend on R&D, adding more tools from genomics, microbiome and machine learning to our already powerful discovery ...